





VASCERN 1st Annual Seminar

Paris, France

13-14 October 2017

Anna Carta <u>Jean Marie Misztela</u>

DG SANTE European Commission





The rationale behind

5000-8000
RARE DISEASES INCLUDING
300
RARE CANCERS AFFECT
30
MILLION PEOPLE IN THE EU



- Many patients affected by a rare or complex condition do not have access to diagnosis and high-quality treatment.
- Expertise and specialist knowledge may be scarce because patient numbers are low
- No country alone has the knowledge and capacity to treat all rare and complex diseases.
- Important delay in diagnosis because lack of knowledge or right referral systems
- Lack of diagnostic capacity (no tests available) and treatments in many cases



Outcome call 2016





24






Networks

26 COUNTRIES



> 300 HOSPITALS

Full Member





Health and Food Safety





Food Safety



24




BOND ERN	Bone Diseases
CRANIO	Craniofacial anomalies and ENT disorders
Endo-ERN	Endocrine Conditions
EpiCARE	Rare and Complex Epilepsies
ERKNet	Kidney Diseases
ERN GENTURIS	Genetic Tumour Risk Syndromes
ERN-EYE	Eye Diseases
ERNICA	inherited and congenital anomalies
ERN-LUNG	Respiratory Diseases
ERN-RND	Neurological Diseases
ERN-Skin	Skin Disorders
ERN Paedcan EURACAN	Rare Paediatric Cancers Solid Adult Cancers

EuroBloodNet	Onco-Hematological Diseases
EUROGEN	Urogenital Diseases
EURO-NMD	Neuromuscular Diseases
GUARD-HEART	Diseases of the Heart
ITHACA	Congenital Malformations and Intellectual Disability
MetabERN	Hereditary metabolic diseases
RARE-LIVER	Hepatological Diseases
ReCONNET	Connective Tissue and Musculoskeletal Diseases
RITA	Immunodeficiency, AutoInflammatory and Auto Immune Diseases
TRANSPLANT- CHILD	Transplantation in Children
VASCERN	Multisystemic Vascular Diseases

Share. Care. Cure.







Clinical virtual care

Research

Knowledge generation

Health and Food Safety

Phases of the ERN life cycle





We

2011-14

Legislation and initial planning

Directive

Implementing decisions

Awareness and communication

project cycle re-initiation

2015-16

Implementation: (Approval stage)

Design and development Assessment tools

Call for ERN

Assessment of Network proposals

Approval of ERNs

2021

Evaluation and update

2017-18

Implementation: (deployment stage)

Establishment

Initial organizational phase

Functioning (initial actions and services)

Partial service production

2019-20

Consolidation

Full service production

Continuous monitoring

Performance indicators and initial outcome assessment

Health and Food Safety





Key role of the Member States

- Recognition of HCP or centers of expertise at national level
- Endorsement of applications
- Board of Member States
 - Development EU ERN strategy
 - Approval of Networks (once positively assessed)






ERNs



Actors involved in the ERN implementation





Commission expert group on rare diseases







National Healthcare **System**





Patients organisations



DG SANTE



DG CONNECT DG RTD JRC

DG DIGIT

INEA CHAFEA

Food Safety





What's on the discussion table?



FRNs BoMS



ERNs' Coordinators

- **Monitoring** Monitoring
- **Information System** Information System
- Affiliated partners
- **Relationship with Industry**
- **Integration with National healthcare** systems

- Cross Borders and **Business continuity**
- Ethics
- Research
- Knowledge generation







Workshop Role of Hospital Managers in Shaping the Future of the European Reference Networks

- To better understand the **benefits and impact** of the ERNs and its Members in the Hospitals host of the ERN Coordinators and Members.
- To identify best practices and possible actions of Hospital Directors and CEOs to support the ERNs members.
- To **align goals and activities** in a win-win patient centered strategy of ERNs, Member States and Hospital managers.

Food Safety

• To discuss **future actions**, links and next steps.

Date: 17 November 2017

Venue: Erasmus University Medical Center Rotterdam

If interested send an email to: <u>SANTE-COORDINATORS-</u>

ERN@ec.europa.eu





Expected impact of the ERNs for patients and professionals

- ✓ improve public and professional awareness of rare and complex diseases
- ✓ increase the likelihood of early and accurate diagnosis and effective treatment where available.
- ✓ platforms for the development of guidelines, training and knowledge-sharing.
- ✓ facilitate large clinical studies to improve understanding and develop new drugs
- ✓ An opportunity for networking with likeminded experts from across Europe — ending the professional isolation that many experts in rare diseases face.





Expected impact of the ERNs for the Healthcare systems and society

- ✓ Innovation in healthcare delivery is the cornerstone of the ERN system
- ✓ Incubators for the development of **digital services** for the provision of virtual healthcare.
- ✓ Development of **new care models**, and innovative medical solutions and devices, changing the way in which treatment itself is delivered.
- ✓ Will help to **boost economies of scale** and ensure a more efficient use of resources, with a positive impact on the sustainability of national healthcare systems.





Pre-publication of Horizon 2020 SC1 Draft Work Programme 2018-2020

EN

Horizon 2020

Work Programme 2018-2020

8. Health, demographic change and wellbeing

Important notice on the Horizon 2020 Work Programme

This draft has not been adopted or endorsed by the European Commission. Any views expressed are the views of the Commission services and may not in any circumstances be regarded as stating an official position of the Commission.

This draft is made public before the adoption of the work programme 2018-2020 to provide potential participants with the currently expected main lines of this work programme. Only the adopted work programme will have legal value.

The adoption of the work programme will be announced on the Horizon 2020 website and on the Participant Portal.

Information and topic descriptions indicated in this draft may not appear in the final work programme; and likewise, new elements may be introduced at a later stage. Any information disclosed by any other party shall not be construed as having been endorsed by or affiliated to the Commission.

The Commission expressly disclaims liability for any future changes of the content of this document.

Rare Disease European Joint Programme Cofund SC1-BHC-04-2018

Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis
SC1-BHC-10-2019

HTA research to support evidencebased healthcare SC1-BHC-26-2018

+ other topics offering rare disease funding opportunities



3 ERN IT TOOLS: 3 Objectives

European collaborative Platform (ECP)

Facilitate Networking between HP's

Circabc

Share documents between restricted workgroup members


CPMS

Support in the Diagnosis & Treatment



Report on ECP platform usage


- From 533 in June to 1303 users for 24 ERNs in October
- 607 helpdesk tickets (mainly for access request)





Report on ECP platform usage


Posts per ERN





Report on ECP platform usage

Activity for the past 6 months 1228 posts





Webex VideoConference Tool experience feedback (ECP only)

- from 3 experiences in June to 120 experiences 10th of October
- Lessons learned
 - Confirmation of Importance of Preparation and Guidelines reading
 - Component installation
 - Audio settings / muting
 - Directions from the meeting chairman are important
 - Best practices/guidelines.
 - TEST BEFORE THE MEETING





ERN Collaborative Platform

Document Management System solution request analysis and assessment

- 23/04 request
- CIRCABC implemented





CIRCABC

(from summer 2017)

Objective

•Share documents between restricted workgroup members

Beneficiaries

Restricted to ERN users only

Key functionality

 Share and manage documents between users

Features

Library







2. Clinical Patient Management **System**

- Clinical Patient Management System is the only official ERN patient management tool, critical for:
 - patient care, diagnosis and treatment;
 - Virtual meetings to discuss and prepare outcome an
 - future clinical research.
 - Collaborative on-line tools
- The focus is first on diagnosis and treatment for patients by providing tools for collaboration, virtual consultations.



2. Clinical Patient Management System

First-line support in the Commission (DG SANTE)

Done

- Second-line support with service provider Done
- User accounts in EULogin system, synchronised to CPMS by DG SANTE Done
 - <u>User authorisation</u> controlled and managed by ERN coordinators/HCP Representatives, implemented by SANTE support To be Done
- Commission will communicate service information whenever necessary





2. Clinical Patient Management System Roll-out steps Done

- 1. Acceptance testing by DG SANTE in July 2017

 Done
- 2. Once accepted, pilot testing by ERN's, test data until data protection notification is approved.

 Done
- 3. For pilot testing: Users need to be authorised and registered in the ERN-CPMS, co-ordinators should ensure this happens correctly, otherwise test account only Done
- 4. After successful pilot and DPO issues resolved, open for production-deployment. Done
- 5. Training material will be prepared and consultant available to support. Done



Data Protection

- Aimed to be fully aligned with the EU current and GDPR (EU Member States have to transpose it into their national law by 6 May 2018, for application by 25 May 2018).
- Status:
 - ECP notification done (for information)
 - CPMS notification: prior check underway, expected to be finished end of October









Commission



Further information:

http://ec.europa.eu/health/ern/policy/index_en.htm

anna.carta@ec.europa.eu jean-marie.misztela@ec.europa.eu

Health and Food Safety